Published on

  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide


  1. 1. S.J. COOPER | Page 1 of 4 SIMON JAMES COOPER, PH.D. sjcooper7@gmail.comBACKGROUNDAfter receiving my Ph.D. in Radiation/Oncology, my research career has focused on translating scientificfindings from bench to bedside while emphasizing patient care. My goals include continuing to interact with theclinical community to further delivery of cutting-edge patient care. While collaborating with clinicians, I share myknowledge of basic scientific techniques, potential markers of disease, and innovative diagnostic tests. I am askilled research presenter and have published scientific review and peer-reviewed articles. I have formed strongbonds with many leading clinicians to collaboratively identify novel biomarkers of disease during my workdeveloping pre-clinical models for cancer therapy, for which I wrote grants and was awarded funding. I lookforward to sharing my passion for the translation of important clinical advances to any audience.WORK EXPERIENCEResearch Associate, Mayo Clinic Florida | 2011 - present Authored peer-reviewed translational research articles published in The Journal of Molecular Biomarkers and Diagnosis and The Journal of Molecular Cancer Therapeutics in collaboration with several Mayo Clinic clinicians. Also wrote and edited grant applications for submission to the NIH and Mayo Clinic internal funding mechanisms using translational findings and clinical collaborations. Led pre-clinical laboratory based studies identifying potential new therapeutic drug combination for the treatment of triple negative breast cancer and clear cell renal cell carcinoma (ccRCC). These investigations are being transitioned into Phase I/II clinical trials. Performed Ad Hoc review for journals like Cancer Research, Oncogene, and Molecular Cancer Research.Senior Research Fellow, Mayo Clinic Florida | 2006 - 2011Senior Research Associate, Arizona Cancer Center | 2001 - 2006Postdoctoral Scholar, University of Kentucky | 1999 - 2001EDUCATION Ph.D., Radiation/Oncology | August 1995 - December 1998 University of Wolverhampton, England and the University of Kentucky B.Sc., Honours, Biomedical Sciences | September 1993 - June 1995 University of Wolverhampton, England HND (Higher National Diploma), Applied Biology | September 1991 - June 1993 Wolverhampton Polytechnic, EnglandHONORS AND AWARDSArizona Cancer Center AACR Travel Award | AACR Annual Meeting, Washington, D.C. | 2006Pfizer Scholar-in-Training Award | Frontiers of Cancer Prevention Conference, Phoenix, AZ | 2003Physiological Society Summer Research Award | University of Wolverhampton | 1995PROFESSIONAL MEMBERSHIPS AND SOCIETIESAssociate Member American Association for Cancer Research (AACR) | 2006 – present
  2. 2. S.J. COOPER | Page 2 of 4 TEACHING AND MENTORING Research Mentor for Yilin Zhang (SURF student 2006-2008), Greg Kennedy (SURF student 2009-2011), Hege Larsen (exchange student 2009-2010), Michelle Hoffman (Ph.D. rotation student 2011), Prakash Vishnu, M.D. (2010-2011), Jacob Mathew, M.D. (2011-present), Christina von Roemeling (Research Technician 2008-present) and Stephen Rohl (Special Projects Associate 2009-2012). Lab Captain. MEDCAMP Program through the College of Medicine, University of Arizona (2004-2006). Research Mentor for Neale Hanke, undergraduate at the University of Arizona. Study for credit (2006). Guest Lecturer. Southwest Environmental Health Sciences Center-Community Outreach and Education Program. College of Pharmacy, University of Arizona (2005). Research Supervisor for Nancy Kim, Medical Student, College of Medicine, University of Arizona (2003) and Thomas Maglinao, undergraduate in the Minority Health Disparities Summer Research Program, University of Arizona (2003). Guest Lecturer. Clinical Immunology, CLS 855. School of Allied Health Professionals, University of Kentucky (1998). Guest Lecturer. Seminars in Advanced Hematology, CLS 501. School of Allied Health Professionals, University of Kentucky (1995-1997).PUBLICATIONSPeer-reviewed PublicationsSimon J. Cooper, Christina Von Roemeling, Kylie H. Kang, Laura A. Marlow, Michael Menefee, Han W. Tun,Edith Perez, John A. Copland. Romidepsin and decitabine synergistically induce apoptosis in clear cell renal cellcarcinoma and triple negative breast cancer cells through the re-expression of sFRP1. Molecular CancerTherapeutics. Oct: 11(10): 2105-15, 2012.Marlow LA, von Roemeling CA, Cooper SJ, Zhang Y, Rohl SD, Arora S, Gonzales IM, Azorsa DO, Reddi HV,Tun HW, Döeppler HR, Storz P, Smallridge RC, Copland JA. Foxo3a drives proliferation in anaplastic thyroidcarcinoma via transcriptional regulation of cyclin A1: A paradigm shift that impacts current therapeuticstrategies. J Cell Sci. Sep 15: 125(Pt18): 4253-63, 2012.Dickinson SE, Olson ER, Zhang J, Cooper SJ, Melton T, Criswell PJ, Casanova A, Dong Z, Hu C, Saboda K,Jacobs ET, Alberts DS, Bowden GT. p38 MAP kinase plays a functional role in UVB-induced mouse skincarcinogenesis. Molecular Carcinogenesis, Jun: 50(6): 469-78, 2011.Armstrong MD, Von Hoff D, Barber B, Marlow LA, von Roemeling C, Cooper SJ, Travis P, Campbell E, Paz-Fumagalli R, Copland JA, Colon-Otero G. An effective personalized approach to rare tumor: prolonged survivalin metastatic pancreatic acinar carcinoma based on genetic analysis and cell line development. J Cancer, Mar8: 2: 142-52, 2011.Jiang L, Marlow LA, Cooper SJ, Roemeling CV, Menke DM, Copland JA, Tun HW. Selective central nervoussystem tropism of primary central nervous system lymphoma. Int J Clin Exp Pathol, Oct 8: 3(8): 763-7, 2010.Marlow LA, DInnocenzi J, Zhang Y, Rohl SD, Cooper SJ, Sebo T, Grant C, McIver B, Kasperbauer JL,Wadsworth JT, Casler JD, Kennedy PW, Highsmith WE, Clark O, Milosevic D, Netzel B, Cradic K, Arora S,Beaudry C, Grebe SK, Silverberg ML, Azorsa DO, Smallridge RC, Copland JA. Detailed MolecularFingerprinting of Four Anaplastic Thyroid Carcinoma Cell Lines and Their Use for Verification of RhoB as aMolecular Therapeutic Target. J Clin Endocrinol Metab. Dec; 95(12): 5338-47, 2010.Cooper SJ, Zou H, Legrand SN, Marlow LA, von Roemeling CA, Radisky DC, Wu KJ, Hempel N, Margulis V,Tun HW, Blobe GC, Wood CG, Copland JA. Loss of type III transforming growth factor-beta receptor expressionis due to methylation of the transcription factor GATA3 in renal cell carcinoma. Oncogene, 29(20); 2905-2915,2010.Tun HW, Marlow LA, von Roemeling CA, Cooper SJ, Kreinest P, Wu K, Luxon BA, Sinha M, Anastasiadis PZ,Copland JA. Pathway signature and cellular differentiation in clear cell renal cell carcinoma. PLoS One. May18;5(5):e10696.2010.
  3. 3. S.J. COOPER | Page 3 of 4 Marlow LA, Reynolds LA, Cleland AS, Cooper SJ, Gumz ML, Kurakata S, Fujiwara K, Zhang Y, Sebo T, GrantC, McIver B, Wadsworth JT, Radisky DC, Smallridge RC, Copland JA. Reactivation of suppressed RhoB is acritical step for the inhibition of anaplastic thyroid cancer growth. Cancer Research, 69(4); 1536-44, 2009.Margulis V, Maity T, Zhang X, Cooper S, Copland J, Wood C. Type III TGF-β receptor mediated apoptosis inrenal cell carcinoma independent of the canonical TFG-β signaling pathway. Accepted: Clinical CancerResearch. May 2008.Hempel N, How T, Cooper SJ, Green TR, Dong M, Copland JA, Wood CG, Blobe GC. Expression of the TypeIII TGF- {beta} Receptor is negatively regulated by TGF- {beta}. Carcinogenesis, 29(5); 905-12, 2008.Howard P. Glauert, Aysegul Eyigor, Job C. Tharappel, Simon Cooper, Eun Y. Lee, and Brett T. Spear (2006).Inhibition of Hepatocarcinogenesis by the Deletion of the p50 Subunit of NF-B in Mice Administered thePeroxisome Proliferator Wy-14,643. Toxicological Sciences, 90(2); 331-6.Cooper S. J., Bowden G. T. (2005). Differential Inhibition of UVB Induced AP-1 and NF-B Transactivation byComponents of the Jun bZIP Domain. Molecular Carcinogenesis, 43(2); 108-16.Simon J. Cooper*, Michael A. Bachelor*, Ewa T. Sikorski and G. Timothy Bowden (2005). Inhibition of p38MAPK and PI3-Kinase Decreases UVB-Induced AP-1 and COX-2 in a SKH-1 Hairless Mouse Model. MolecularCancer Research, 3(2); 90-99. *Equal contribution.Ming Zhu, Yeusheng Zhang, Simon Cooper, Ewa Sikorski, John Rohwer, G. Timothy Bowden (2004). Phase IIenzyme inducer, Sulforaphane, inhibits UVB-induced AP-1 activation in human keratinocytes by a novelmechanism. Molecular Carcinogenesis, 41; 179-186.Cooper SJ, MacGowan J, Ranger-Moore J, Young MR, Colburn NH, Bowden GT. (2003). Expression ofdominant negative c-jun inhibits ultraviolet B-induced squamous cell carcinoma number and size in an SKH-1hairless mouse model. Molecular Cancer Research, 1(11); 848-54.Li Y, Tharappel JC, Cooper S, Glenn M, Glauert HP, Spear BT (2000). Expression of the hydrogen peroxide-generating enzyme fatty acyl CoA oxidase activates NF-kappaB. DNA Cell Biology, 19(2); 113-20.Cooper SJ, Gass C, Birch NJ, Phillips JD, Gallicchio VS, Doukas MA (2000). Production by a murine bonemarrow stroma cell of stem cell factor (SCF) is inhibited by exposure to lithium and/or radiation. Journal of Traceand Microprobe Techniques, 18(4); 583-592.Cooper SJ, Gass C, Bryson S, DelaPuca R, Birch NJ, Gallicchio VS, Doukas MA (1998). Radiomodulation bylithium on marrow stromal support of granulopoiesis. Journal of Trace and Microprobe Techniques, 16(2); 9-16.Review ArticlesSimon J. Cooper, Han W. Tun, Stephen M. Roper, Yunee Kim, Thomas Kislinger, Richard R. Drake, John A.Copland. Current status of biomarker discovery in human clear cell renal cell carcinoma. J MolBiomark Diagn S2:005. doi:10.4172/2155-9929.S2-005 2012.Cooper SJ, Bowden GT. Ultraviolet B regulation of Transcription factor families: roles of nuclear factor-kappa B(NF-kappaB) and activator protein-1 (AP-1) in UVB induced skin carcinogenesis. Curr Cancer Drug Targets, 7(4);325-34, 2007.Book ChaptersSJ Cooper, C Gass, NJ Birch, JD Phillips, VS Gallicchio, MA Doukas (1999).Production by a murine marrow stroma cell of stem cell factor (SCF) is inhibited by exposure to lithium and/orradiation. In: Lithium – 50 Years: Recent advances in Biology and Medicine. (Eds) Lucas KC, Becker RWand Gallicchio VS, pp 219-230, Weidner Publishing, Cheshire, Connecticut.PRESENTATIONSOral Presentations Post-doctoral seminar series, Mayo Clinic Jacksonville (2011) “A role for GATA3 in clear cell renal cell carcinoma.”
  4. 4. S.J. COOPER | Page 4 of 4  Post-doctoral seminar series, Mayo Clinic Jacksonville (2011) “NPTX2: a novel molecular target for therapy in clear cell renal cell carcinoma.” Post-doctoral seminar series, Mayo Clinic Jacksonville (2009) “GATA3 is a critical transcription factor for differentiated function in the kidney.” Cell Signaling Meeting, South Padre Texas (2008) “Regulation of the Human Type III TGF Receptor.” Post-doctoral seminar series, Mayo Clinic Jacksonville (2008) “Transcriptional Regulation of the Human Type III TGF Receptor.” Cell Signaling Meeting, South Padre Texas (2007) “Transcriptional Regulation of the Human Type III TGF Receptor.” Cancer Prevention and Control Grand Rounds Seminar, Arizona Cancer Center (2004) “Identification of potential molecular targets for the chemoprevention of UVB-induced skin carcinogenesis.” Cancer Prevention and Control Grand Rounds Seminar, Arizona Cancer Center (2002) “Role of AP-1 and NF-B in UVB induced skin carcinogenesis.” Invited Seminar, Arizona Cancer Center (2001) “Transgenic models to study NF-B in the response to peroxisome proliferators.” Department of Microbiology and Immunology, University of Kentucky (2001) “Transgenic models to study NF-B in the response to peroxisome proliferators.” 50th Anniversary of Lithium Conference, Lexington KY (1999) “Production by a representative of the murine haematopoietic bone marrow stroma of the soluble form of the cytokine stem cell factor (SCF) is inhibited by exposure to lithium and/or radiation.”Poster Presentations AACR Annual Meeting (Orlando, 2011) “Negative transcriptional regulation of the human type III TGF receptor in ccRCC. Cooper SJ.” AACR Annual Meeting (San Diego, 2008) “Transcriptional regulation of the human type III TGF receptor. Cooper SJ.” Nineteenth International Conference on Antiviral Research (San Juan, Puerto Rico, 2006) “Inhibition of Murine Cytomegalovirus by Second Generation Ribonucleotide Reductase Inhibitors Didox and Trimidox. Mohammed Inayat, Simon Cooper, Donald Smee, Vincent Gallicchio, Beth Garvey, Howard Elford, Oliver Oakley.” AACR Annual Meeting (Washington, D.C., 2006) “Activation of NF- B by Ultraviolet light B is through two different phosphorylation events of its inhibitor molecule I B . Simon J Cooper.” Proceedings of the Frontiers of Cancer Prevention Research Conference (Phoenix, Arizona, 2003) “A dominant negative c-jun (TAM67) interacts with members of the NF-B protein family inhibiting UVB induced NF-B transactivation. Simon J Cooper.” Proceedings of the Frontiers of Cancer Prevention Research Conference (Phoenix, Arizona, 2003) “Modulation of p38 and PI-3 Kinase following acute UVB exposure in SKH-1 mouse epidermis. Michael A. Bachelor, Simon J Cooper, Ewa Sikorski and G. Tim Bowden.” Experimental Biology 2001 (Orlando, Florida, 2001) “Mouse models to explore the role of NF-B in the response to peroxisome proliferators. Simon Cooper.” AACR Annual Meeting (New Orleans, 1998) “Amifostine and its active metabolite WR-1065 prevent the acute phase irradiation response of bone marrow stroma, as measured by stromal support and hematopoietic progenitors. Simon Cooper.” Life Sciences Research Day, University of Kentucky (1997) “Radiomodulation by lithium in marrow support of granulopoiesis. Simon Cooper.”AWARDED RESEARCH GRANTS A Diagnostic Tool for Micrometastatic Disease in ccRCC. Mayo Clinic Marriot Award | Type: Developmental Identification of Potential Agents That Block the Interactions between the Transcription Factors NF- B and AP-1: Two Families of Transcription Factors That Are Involved in the Promotion of UVB Induced Squamous Cell Carcinoma of the Skin. Cancer Research Foundation of America | Type: FellowshipREFERENCES AVAILABLE UPON REQUEST